Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259


Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.

Li G, Wang Z, Zhang C, Liu X, Cai J, Wang Z, Hu H, Wu F, Bao Z, Liu Y, Zhao L, Liang T, Yang F, Huang R, Zhang W, Jiang T.

Oncoimmunology. 2017 Jul 28;6(8):e1328339. doi: 10.1080/2162402X.2017.1328339. eCollection 2017.


TLR4 interaction with LPS in glioma CD133+ cancer stem cells induces cell proliferation, resistance to chemotherapy and evasion from cytotoxic T lymphocyte-induced cytolysis.

Che F, Yin J, Quan Y, Xie X, Heng X, Du Y, Wang L.

Oncotarget. 2017 Jun 21;8(32):53495-53507. doi: 10.18632/oncotarget.18586. eCollection 2017 Aug 8.


MicroRNA-1179 inhibits glioblastoma cell proliferation and cell cycle progression via directly targeting E2F transcription factor 5.

Xu X, Cai N, Zhi T, Bao Z, Wang D, Liu Y, Jiang K, Fan L, Ji J, Liu N.

Am J Cancer Res. 2017 Aug 1;7(8):1680-1692. eCollection 2017.


MicroRNA-590-3p enhances the radioresistance in glioblastoma cells by targeting LRIG1.

Chen L, Wang W, Zhu S, Jin X, Wang J, Zhu J, Zhou Y.

Exp Ther Med. 2017 Aug;14(2):1818-1824. doi: 10.3892/etm.2017.4697. Epub 2017 Jun 28.


Upregulation of DACT2 suppresses proliferation and enhances apoptosis of glioma cell via inactivation of YAP signaling pathway.

Tan Y, Li QM, Huang N, Cheng S, Zhao GJ, Chen H, Chen S, Tang ZH, Zhang WQ, Huang Q, Cheng Y.

Cell Death Dis. 2017 Aug 10;8(8):e2981. doi: 10.1038/cddis.2017.385.


Genetically Engineered Multilineage-Differentiating Stress-Enduring Cells as Cellular Vehicles against Malignant Gliomas.

Yamasaki T, Wakao S, Kawaji H, Koizumi S, Sameshima T, Dezawa M, Namba H.

Mol Ther Oncolytics. 2017 Jun 15;6:45-56. doi: 10.1016/j.omto.2017.06.001. eCollection 2017 Sep 15.


Assessment Effects of Resveratrol on Human Telomerase Reverse Transcriptase Messenger Ribonucleic Acid Transcript in Human Glioblastoma.

Mirzazadeh A, Kheirollahi M, Farashahi E, Sadeghian-Nodoushan F, Sheikhha MH, Aflatoonian B.

Adv Biomed Res. 2017 Jun 27;6:73. doi: 10.4103/2277-9175.209047. eCollection 2017.


Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression.

Yu D, Khan OF, Suvà ML, Dong B, Panek WK, Xiao T, Wu M, Han Y, Ahmed AU, Balyasnikova IV, Zhang HF, Sun C, Langer R, Anderson DG, Lesniak MS.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6147-E6156. doi: 10.1073/pnas.1701911114. Epub 2017 Jul 10.


IL13RA2 targeted alpha particle therapy against glioblastomas.

Sattiraju A, Solingapuram Sai KK, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz A.

Oncotarget. 2017 Jun 27;8(26):42997-43007. doi: 10.18632/oncotarget.17792.


TRIM45 functions as a tumor suppressor in the brain via its E3 ligase activity by stabilizing p53 through K63-linked ubiquitination.

Zhang J, Zhang C, Cui J, Ou J, Han J, Qin Y, Zhi F, Wang RF.

Cell Death Dis. 2017 May 25;8(5):e2831. doi: 10.1038/cddis.2017.149.


MicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras.

Zhi T, Jiang K, Zhang C, Xu X, Wu W, Nie E, Yu T, Zhou X, Bao Z, Jin X, Zhang J, Wang Y, Liu N.

Am J Cancer Res. 2017 Apr 1;7(4):982-998. eCollection 2017.


Synergistic Effects of Arsenic Trioxide and Radiation: Triggering the Intrinsic Pathway of Apoptosis

Moloudi K, Neshasteriz A, Hosseini A, Eyvazzadeh N, Shomali M, Eynali S, Mirzaei E, Azarnezhad A.

Iran Biomed J. 2017 May 1;21(5):330-337. doi: 10.18869/acadpub.ibj.21.5.330. Print 2017 Sep.


Mesenchymal stem cells differentially affect the invasion of distinct glioblastoma cell lines.

Breznik B, Motaln H, Vittori M, Rotter A, Lah Turnšek T.

Oncotarget. 2017 Apr 11;8(15):25482-25499. doi: 10.18632/oncotarget.16041.


MiR-29b inhibits the growth of glioma via MYCN dependent way.

Sun G, Lu J, Zhang C, You R, Shi L, Jiang N, Nie D, Zhu J, Li M, Guo J.

Oncotarget. 2017 Jul 11;8(28):45224-45233. doi: 10.18632/oncotarget.16780.


Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma.

Song Y, Zheng S, Wang J, Long H, Fang L, Wang G, Li Z, Que T, Liu Y, Li Y, Zhang X, Fang W, Qi S.

Oncotarget. 2017 Jun 27;8(26):41947-41962. doi: 10.18632/oncotarget.16710.


Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.

Velpula KK, Guda MR, Sahu K, Tuszynski J, Asuthkar S, Bach SE, Lathia JD, Tsung AJ.

Oncotarget. 2017 May 30;8(22):35639-35655. doi: 10.18632/oncotarget.16767.


The integrative metabolomic-transcriptomic landscape of glioblastome multiforme.

Heiland DH, Wörner J, Gerrit Haaker J, Delev D, Pompe N, Mercas B, Franco P, Gäbelein A, Heynckes S, Pfeifer D, Weber S, Mader I, Schnell O.

Oncotarget. 2017 Jul 25;8(30):49178-49190. doi: 10.18632/oncotarget.16544.


Myeloid-derived suppressor cells in gliomas.

Gieryng A, Kaminska B.

Contemp Oncol (Pozn). 2016;20(5):345-351. doi: 10.5114/wo.2016.64592. Epub 2016 Dec 20. Review.


Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.

Mei X, Chen YS, Chen FR, Xi SY, Chen ZP.

Neuro Oncol. 2017 Aug 1;19(8):1109-1118. doi: 10.1093/neuonc/nox016.


Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas.

Zhao Z, Meng F, Wang W, Wang Z, Zhang C, Jiang T.

Sci Data. 2017 Mar 14;4:170024. doi: 10.1038/sdata.2017.24.

Supplemental Content

Support Center